1Semczuk A, Postawski K, Przadka D, et al. K-ras gene point mutations and p21ras immunostaining in human o- varian tumors [J]. Eur J Gynaecol Oncol, 2004, 25 (4) : 484-488.
2Klimcakova E, Chenard V, McGuirk S, et al. PGC-1α promotes the growth of ErbB2/Neu-induced mammary tumors by regulating nutrient supply [J]. Cancer Res, 2012, 72(6) : 1538-1546.
3Lambropoulou M, Papadopoulos N, Tripsianis G, et al. Co-expression of survivin, c-erbB2, and cyclooxygenase-2 (COX-2) :prognostic value and survival of endometrial cancer patients[J]. J Cancer Res Clin Oncol, 2010, 136 (3) :427-435.
4Ozkan C, Gumuskaya B, Yaman S, et al. ERCC1 expression in triple negative breast cancer [J]. J BUON, 2012, 17(2) :271-276.
5Deloia J A, Bhagwat N R, Darcy K M, et al. Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum [ J ]. Gynecol Oncol, 2012, 126(3) :448-454.
6Bajpai D, Banerjee A, Pathak S, et al. Decreased expres- sion of DNA repair genes (XRCC1, ERCC1, ERCC2, and ERCC4) in squamous intraepithelial lesion and invasive squamous cell carcinoma of the cervix [J]. Mol Cell Biochem, 2013, 377(1-2) :45-53.
7Cheng H, Zhang Z, Borczuk A, et al. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1- low non-small cell lung cancer cells [J]. Carcinogene- sis, 2013, 34(4):739-749.
8Kim M R, Jeong E G, Chae B, et al. Pro-apoptotic PU- MA and anti-apoptotic phospho-BAD are highly expressed in colorectal carcinomas[J]. Dig Dis Sci, 2007, 52(10) :2751-2756.
9Witton C J, Reeves J R, Going J J, et al. Expression of the HER1-4 family of receptor tyrosine kinases in breast [J]. J Pathol, 2003, 200(3) :290-297.
10Brabender J, Danenberg D, Metzger R, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival [J]. Clin Cancer Res, 2001, 7(7) :1850-1855.
